Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate D-1553 in Subjects With Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with histologically proven, locally advanced, unresectable and/or metastatic NSCLC for which no standard treatment is available or the subject is refractory to or intolerant of existing standard treatment.~* Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA. Historical, local laboratory result (up to 5 years prior to this study) can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C mutation by a central laboratory.~* Subject has measurable disease according to RECIST, v1.1~Exclusion Criteria:~* Subject with unstable or progressive central nervous system (CNS) metastases.~* Subjects with clinically significant cardiovascular disease~* Subject with interstitial lung disease (ILD) or any active systemic infection including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.~* Subject has impaired gastrointestinal (GI) function or GI diseases that may significantly alter the absorption or metabolism of oral medications.~* Subject is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1a Dose escalation of D-1553 (Type: EXPERIMENTAL): Phase 1a will evaluate up to sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation
- Phase 1b Dose expansion of D-1553 (Type: EXPERIMENTAL): Phase 1b will evaluate more subjects with up to 2 different doses of D-1553 to confirm the recommended phase 2 dose.
- Phase 2 of D-1553 monotherapy (Type: EXPERIMENTAL): Phase 1b will evaluate more subjects at the recommended phase 2 dose of D-1553 to evaluate the efficacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).